Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04389671 · ClinicalTrials.gov registry record · Phase 2
The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19)
A Phase 2 study, sponsored by Windtree Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT04389671 is a Phase 2 study that has completed, run by Windtree Therapeutics. The registered enrollment target is 20 participants.
The verdict
NCT04389671, a Phase 2 study, has completed, sponsored by Windtree Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a multicenter, single-treatment study. Subjects will consist of adults with COVID-19 associated acute lung injury who are being cared for in a critical care environment.
Interventions
- DRUG Lucinactant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-01-05 |
| Est. Completion | 2022-02-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04389671
The ClinicalTrials.gov registry entry for NCT04389671 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Windtree Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lucinactant is the first listed.
NCT04389671 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04389671 about?
NCT04389671 is a clinical study titled "The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19)". This is a multicenter, single-treatment study. Subjects will consist of adults with COVID-19 associated acute lung injury who are being cared for in a critical care environment.
What is the current status of trial NCT04389671?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2021-01-05. Estimated completion is 2022-02-20.
What interventions are being tested in trial NCT04389671?
The interventions under investigation include: Lucinactant (DRUG).
Who is sponsoring clinical trial NCT04389671?
This trial is sponsored by Windtree Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.